136 related articles for article (PubMed ID: 2932585)
1. Effects of intraperitoneal administration of OK-432 for patients with advanced cancer.
Toge T; Yamada H; Aratani K; Kameda A; Kuroi K; Hisamatsu K; Hattori T
Jpn J Surg; 1985 Jul; 15(4):260-5. PubMed ID: 2932585
[TBL] [Abstract][Full Text] [Related]
2. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
3. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.
Katano M; Torisu M
Surgery; 1983 Mar; 93(3):365-73. PubMed ID: 6600854
[TBL] [Abstract][Full Text] [Related]
4. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients.
Yamaguchi Y; Satoh Y; Miyahara E; Noma K; Funakoshi M; Takashima I; Sawamura A; Toge T
Anticancer Res; 1995; 15(5B):2201-6. PubMed ID: 8572625
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
Katano M
Fukuoka Igaku Zasshi; 1981 Oct; 72(10):543-55. PubMed ID: 7327499
[No Abstract] [Full Text] [Related]
6. [A case of advanced gastric cancer responsive to intratumoral OK-432 injection].
Sakai Y; Maeda M; Koyama W; Totsuka S; Sakamoto S; Kanayama M
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1978-80. PubMed ID: 3382244
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-mediated tumor cell destruction in cancer ascites.
Katano M; Torisu M
Cancer; 1982 Jul; 50(1):62-8. PubMed ID: 7083126
[TBL] [Abstract][Full Text] [Related]
8. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
[TBL] [Abstract][Full Text] [Related]
9. [Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume].
Katano M; Mizoguchi T; Yamamoto H; Hisatsugu T; Torisu M
Nihon Geka Gakkai Zasshi; 1987 Dec; 88(12):1676-83. PubMed ID: 3447033
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect in peritoneal carcinomatosis of intraperitoneal administration of a streptococcal preparation, OK-432: I. Experimental study in the rat.
Saji S; Umemoto T; Kida H; Sakata K
J Surg Oncol; 1985 Sep; 30(1):46-51. PubMed ID: 4079418
[TBL] [Abstract][Full Text] [Related]
11. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432.
Kawagoe K; Masuda H
Jpn J Clin Oncol; 1986 Jun; 16(2):137-42. PubMed ID: 3735703
[TBL] [Abstract][Full Text] [Related]
12. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
13. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
Mori H; Itoh N; Tamaya T
Immunopharmacol Immunotoxicol; 1989; 11(1):33-53. PubMed ID: 2503555
[TBL] [Abstract][Full Text] [Related]
15. A patient with gastric carcinoma improved remarkably on intraperitoneal OK-432 therapy.
Yamagishi H; Ishibashi H; Kodama M; Tanaka T; Harada Y; Hashimoto I
Jpn J Surg; 1982; 12(6):434-41. PubMed ID: 7166915
[TBL] [Abstract][Full Text] [Related]
16. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-mediated tumor cell destruction in cancer ascites. II. A OK-432 attracts killer neutrophils through activation of complement C5.
Fujimura T; Torisu M
Clin Immunol Immunopathol; 1987 May; 43(2):174-84. PubMed ID: 3105938
[TBL] [Abstract][Full Text] [Related]
18. [Intraperitoneal cavity injection of OK-432 with fresh human serum in a case of carcinomatous peritonitis--determination on the complement-derived chemotactic factor].
Kato H; Kondo Y; Tanigawa M; Kin R; Sugino S; Kondo M
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3251-5. PubMed ID: 3777961
[TBL] [Abstract][Full Text] [Related]
19. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
20. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.
Torisu M; Katano M; Kimura Y; Itoh H; Takesue M
Surgery; 1983 Mar; 93(3):357-64. PubMed ID: 6187080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
